Health ❯Healthcare ❯Pharmaceuticals

Weight Loss

GLP-1 Drugs Obesity Treatments Mounjaro Wegovy GLP-1 Medications Semaglutide Clinical Trials Orforglipron GLP-1 Receptor Agonists Tirzepatide

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Investors punished the stock following modest weight-loss data, with Lilly preparing a year-end FDA submission for a global roll-out.

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

Mouse Study Finds Ozempic Reduces Lean Mass and Shrinks Organs

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

UK Regulator Probes Pancreatitis Cases Linked to GLP-1 Weight-Loss Drugs

Novo Nordisk Launches Wegovy Weight-Loss Drug in India

NHS Empowers GPs to Prescribe Mounjaro for Severe Obesity

Experimental Drug SANA Boosts Fat Thermogenesis to Promote Weight Loss Ahead of Phase 2 Trials

Novo Nordisk’s Amycretin Delivers Up to 24% Early Weight Loss in Dual-Form Trials

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

Noom Introduces Personalized Microdoses of Compounded Wegovy Ahead of FDA Deadline

Trump's Executive Order Targets U.S. Drug Price Disparities

Weight Management Revolution: GLP-1 Drugs Dominate as Pills Emerge

UK to Trial Pharmacy-Based NHS Weight-Loss Jab Prescriptions

Novo Nordisk Partners with Telehealth Firms to Expand Wegovy Access

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Hims & Hers Expands Weight-Loss Offerings with New Medications

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients